Lauren M. Green

Articles

HPV Vaccine May Benefit Women Previously Exposed to the Virus

April 21st 2015

HPV vaccination may offer protection against HPV-related cancers across multiple tumor sites in women aged 18-25 who had been previously exposed to HPV.

Joan Lunden Paints a Picture of Breast Cancer From the Patient's Perspective

February 28th 2015

Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.

Early Intervention Essential for Proper Lymphedema Management

February 27th 2015

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

MBCC Embraces Revolution in Breast Cancer Care

February 26th 2015

The landscape of breast cancer care is shifting rapidly, but that doesn't worry the organizers of the 32nd Annual Miami Breast Cancer Conference.

Use With Caution: Active Surveillance in Patients With Intermediate-Risk Prostate Cancer

February 23rd 2015

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients.

New Approaches Emerge for Treating ALL, Yet Challenges Remain

February 23rd 2015

The treatment landscape for acute lymphoblastic leukemia (ALL) is changing, pointing to promising new approaches clinicians can use in practice.

Two Studies Explore Role of Radiation, Bisphosphonates in Prostate Cancer Care

January 19th 2015

For older men with prostate cancer, adding radiation to hormone therapy is both tolerable and effective in reducing the number of deaths.

Higher Vitamin D Levels Improve Survival for Patients With mCRC

January 12th 2015

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment.

Women With Triple-Negative Breast Cancer May Reap Greater Survival Benefit From Nutrition Intervention

December 12th 2014

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptorâ€“negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

Tamoxifen's Sustained Power to Prevent Breast Cancer in High-Risk Women Confirmed

December 11th 2014

Five years of tamoxifen continues to offer protection against breast cancer, reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.

Early Data Find the PI3K Inhibitor Pictilisib Benefits a Subset of Patients With MBC

December 10th 2014

The addition of the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer yielded some intriguing findings in the phase II FERGI study.

Race, Hospital, and Insurance Status Matters For Patients With Inoperable Stage I Lung Cancer

December 2nd 2014

Despite the proven benefits of stereotactic body radiotherapy (SBRT) for patients with inoperable stage I nonâ€“small cell lung cancer (NSCLC), whether such patients are offered it depends on their race, insurance status, and the type of facility where they are being treated.

New Research Focuses on Personalized Treatments in Ovarian Cancer

November 6th 2014

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

Roboz Discusses Progress, Challenges in AML

November 5th 2014

When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what's ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.

Screening for Distress Now a Routine Part of Quality Cancer Care-At Last

September 23rd 2014

At the 2014 ASCO meeting, OncologyLive sat down with Jimmie C. Holland, MD, the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan Kettering Cancer Center and the recipient of the 2014 Giants of Cancer Careâ„¢ Award for her pioneering contributions in the field of supportive care.

Individualized Treatment Strategies Needed for Managing Breakthrough Cancer Pain

September 9th 2014

Breakthrough pain is a common and disabling reality for patients with advanced cancer. Its root causes vary, and experts agree that this type of pain is often inadequately managed.

DHEA Therapy Offers Relief From Vaginal Symptoms in Cancer Survivors

August 21st 2014

A randomized multicenter trial examining the efficacy of adding dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women.

MRI-Guided Ultrasound Relieves Pain of Bone Metastases

June 19th 2014

An MRI-guided focused ultrasound approach using heat to alleviate the pain commonly associated with bone metastases has proven to be safe and effective in a multi-center phase III clinical trial, yielding a 64% response rate.

'Smart' Alkylator TH-302 Shows Clinical Benefit in Early Multiple Myeloma Trial

June 2nd 2014

The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.

New Study Findings Confirm Pembrolizumab's Durable Responses in Metastatic Melanoma

June 2nd 2014

The anti-PD 1 checkpoint inhibitor, pembrolizumab, continues to deliver impressive results in patients with advanced melanoma-producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.